Image credit: shutterstock.com
Lupin has entered into an agreement with TTP (The Technology Partnership) to acquire the exclusive worldwide rights to develop, manufacture and commercialise inhalation products using TTP’s soft-mist inhalation technology platform. By leveraging this technology, Lupin expects to provide healthcare professionals with alternative solutions for delivering affordable inhaled medicines to patients across the globe.
Soft-mist inhalation (SMI) technology allows for the delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants. The individual doses are delivered using a precisely engineered nozzle system to produce a slow-moving and long-sustaining aerosol cloud. Mumbai-based pharma firm Lupin anticipates applications across respiratory care.
Lupin and TTP will jointly develop the device. Lupin will commercially manufacture the device through its network of in-house and external manufacturing locations. Lupin will also develop and manufacture formulations to be delivered through the device, obtain the necessary regulatory approvals, and commercialise the products globally.
